{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:30:52Z","timestamp":1781170252835,"version":"3.54.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":1757,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>The coronavirus disease (COVID-19) pandemic struck an immunologically naive, globally interconnected population. In the face of a new infectious agent causing acute respiratory failure for which there were no known effective therapies, rapid, often pragmatic trials were necessary to evaluate potential treatments, frequently starting with medications that are already marketed for other indications. Early in the pandemic, hydroxychloroquine and azithromycin were two such candidates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the relative efficacy of hydroxychloroquine and azithromycin among hospitalized patients with COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a randomized clinical trial of hydroxychloroquine versus azithromycin among hospitalized patients with COVID-19. Treatment was 5 days of study medication. The primary endpoint was the COVID ordinal outcomes scale at Day 14. Secondary endpoints included hospital-, intensive care unit\u2013, and ventilator-free days at Day 28. The trial was stopped early after the enrollment of 85 patients when a separate clinical trial concluded that a clinically important effect of hydroxychloroquine over placebo was definitively excluded. Comparisons were made a priori using a proportional odds model from a Bayesian perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We enrolled 85 patients at 13 hospitals over 11 weeks. Adherence to study medication was high. The estimated odds ratio for less favorable status on the ordinal scale for hydroxychloroquine versus azithromycin from the primary analysis was 1.07, with a 95% credible interval from 0.63 to 1.83 with a posterior probability of 60% that hydroxychloroquine was worse than azithromycin. Secondary outcomes displayed a similar slight preference for azithromycin over hydroxychloroquine. QTc prolongation was rare and did not differ between groups. The 20 safety outcomes were similar between arms, with the possible exception of postrandomization-onset acute kidney injury, which was more common with hydroxychloroquine (15% vs. 0%). Patients in the hydroxychloroquine arm received remdesivir more often than those in the azithromycin arm (19% vs. 2%). There was no apparent association between remdesivir use and acute kidney injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although early termination limits the precision of our results, we found no suggestion of substantial efficacy for hydroxychloroquine over azithromycin. Acute kidney injury may be more common with hydroxychloroquine than azithromycin, although this may be due to the play of chance. Differential use of remdesivir may have biased our results in favor of hydroxychloroquine. Our results are consistent with conclusions from other trials that hydroxychloroquine cannot be recommended for inpatients with COVID-19; azithromycin may merit additional investigation.<\/jats:p>\n                    <jats:p>Clinical trial registered with http:\/\/www.clinicaltrials.gov\/ (NCT04329832).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202008-940oc","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T16:29:31Z","timestamp":1604939371000},"page":"590-597","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":30,"title":["Hydroxychloroquine versus Azithromycin for Hospitalized Patients with COVID-19. Results of a Randomized, Active Comparator Trial"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1206-6261","authenticated-orcid":false,"given":"Samuel M.","family":"Brown","sequence":"first","affiliation":[{"name":"Pulmonary and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-234X","authenticated-orcid":false,"given":"Ithan","family":"Peltan","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine"},{"name":"Infectious Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Leither","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-3315","authenticated-orcid":false,"given":"Brandon J.","family":"Webb","sequence":"additional","affiliation":[{"name":"Infectious Diseases, and"},{"name":"Infectious Diseases"},{"name":"Infectious Diseases, Stanford University, Stanford, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Starr","sequence":"additional","affiliation":[{"name":"Hospital Medicine, Intermountain Medical Center, Murray, Utah"},{"name":"Hospital Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin K.","family":"Grissom","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-2572","authenticated-orcid":false,"given":"Whitney R.","family":"Buckel","sequence":"additional","affiliation":[{"name":"Pharmacy Services and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendu","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Pediatric Inpatient Medicine, and"},{"name":"Healthcare Delivery Institute, Intermountain Healthcare, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Butler","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Groat","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Haaland","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Population Health Sciences, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ying","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Population Health Sciences, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Harris","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Johnson","sequence":"additional","affiliation":[{"name":"Hospital Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Robert","family":"Paine","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Greene","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Population Health Sciences, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"2026012203473706400_bib1","article-title":"Remdesivir for the treatment of Covid-19\u2014preliminary report","author":"Beigel","journal-title":"N Engl J Med"},{"key":"2026012203473706400_bib2","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","author":"Goldman","journal-title":"N Engl J Med"},{"key":"2026012203473706400_bib3","article-title":"Dexamethasone in hospitalized patients with covid-19\u2014preliminary report","author":"The RECOVERY Collaborative Group","journal-title":"N Engl J Med"},{"key":"2026012203473706400_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S2213-2600(20)30127-2","article-title":"Treatment for severe acute respiratory distress syndrome from COVID-19","volume":"8","author":"Matthay","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012203473706400_bib5","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012203473706400_bib6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today\u2019s diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"2026012203473706400_bib7","first-page":"55","article-title":"Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells","volume":"24","author":"van den Borne","year":"1997","journal-title":"J Rheumatol"},{"key":"2026012203473706400_bib8","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/infdis\/164.4.830","article-title":"Chloroquine inhibits tumor necrosis factor production by human macrophages in vitro","volume":"164","author":"Picot","year":"1991","journal-title":"J Infect Dis"},{"key":"2026012203473706400_bib9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/rheumatology\/kei282","article-title":"Chloroquine inhibits production of TNF-\u03b1, IL-1\u03b2 and IL-6 from lipopolysaccharide-stimulated human monocytes\/macrophages by different modes","volume":"45","author":"Jang","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2026012203473706400_bib10","first-page":"803","article-title":"Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells","volume":"20","author":"Sperber","year":"1993","journal-title":"J Rheumatol"},{"key":"2026012203473706400_bib11","article-title":"Hydroxychloroquine sulfate for the treatment of common 2019 coronavirus disease (COVID-19) Preliminary study of patients Journal of Zhejiang University (Medical Edition)","author":"Jun","year":"2020 [ 2020  1]"},{"key":"2026012203473706400_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"key":"2026012203473706400_bib13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In Vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026012203473706400_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"2026012203473706400_bib15","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1021\/jm0601856","article-title":"Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities","volume":"49","author":"Biot","year":"2006","journal-title":"J Med Chem"},{"key":"2026012203473706400_bib16","doi-asserted-by":"crossref","DOI":"10.1101\/2020.03.22.20040758","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial [preprint]","author":"Chen","year":"2020"},{"key":"2026012203473706400_bib17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1183\/09031936.00095809","article-title":"Azithromycin induces anti-viral responses in bronchial epithelial cells","volume":"36","author":"Gielen","year":"2010","journal-title":"Eur Respir J"},{"key":"2026012203473706400_bib18","doi-asserted-by":"crossref","first-page":"28698","DOI":"10.1038\/srep28698","article-title":"Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients","volume":"6","author":"Menzel","year":"2016","journal-title":"Sci Rep"},{"key":"2026012203473706400_bib19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1378\/chest.11-1908","article-title":"Macrolide antibiotics and survival in patients with acute lung injury","volume":"141","author":"Walkey","year":"2012","journal-title":"Chest"},{"key":"2026012203473706400_bib20","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1186\/s40064-016-2866-1","article-title":"Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis","volume":"5","author":"Kawamura","year":"2016","journal-title":"Springerplus"},{"key":"2026012203473706400_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/atm.2017.12.25","article-title":"Macrolide therapy is associated with reduced mortality in acute respiratory distress syndrome (ARDS) patients","volume":"6","author":"Simonis","year":"2018","journal-title":"Ann Transl Med"},{"key":"2026012203473706400_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"key":"2026012203473706400_bib23","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1513\/AnnalsATS.202004-309SD","article-title":"Hydroxychloroquine versus Azithromycin for hospitalized patients with suspected or confirmed COVID-19 (HAHPS): protocol for a pragmatic, open-label, active comparator trial","volume":"17","author":"Brown","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203473706400_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2026012203473706400_bib25","doi-asserted-by":"crossref","DOI":"10.1101\/2020.07.15.20151852","article-title":"Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial [preprint]","author":"Horby","year":"2020"},{"key":"2026012203473706400_bib26","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026012203473706400_bib27","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026012203473706400_bib28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2020.1787","article-title":"Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit","volume":"5","author":"Bessi\u00e8re","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026012203473706400_bib29","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19","author":"Cavalcanti","journal-title":"N Engl J Med"},{"key":"2026012203473706400_bib30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.kint.2020.05.001","article-title":"Autophagy inhibition by chloroquine and hydroxychloroquine could adversely affect acute kidney injury and other organ injury in critically ill patients with COVID-19","volume":"98","author":"Edelstein","year":"2020","journal-title":"Kidney Int"},{"key":"2026012203473706400_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2026012203473706400_bib32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41419-018-0378-3","article-title":"Hydroxychloroquine attenuates renal ischemia\/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation","volume":"9","author":"Tang","year":"2018","journal-title":"Cell Death Dis"},{"key":"2026012203473706400_bib33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1161\/HYPERTENSIONAHA.114.03587","article-title":"Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus","volume":"64","author":"G\u00f3mez-Guzm\u00e1n","year":"2014","journal-title":"Hypertension"},{"key":"2026012203473706400_bib34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1378\/chest.09-3071","article-title":"Incidence and prognostic implications of acute kidney injury on admission in patients with community-acquired pneumonia","volume":"138","author":"Akram","year":"2010","journal-title":"Chest"},{"key":"2026012203473706400_bib35","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1053\/j.ajkd.2007.07.018","article-title":"The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis","volume":"50","author":"Coca","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2026012203473706400_bib36","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.3399\/bjgp10X514819","article-title":"How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trials","volume":"60","author":"Smelt","year":"2010","journal-title":"Br J Gen Pract"},{"key":"2026012203473706400_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1513\/pats.200706-072JK","article-title":"Usual care as the control group in clinical trials of nonpharmacologic interventions","volume":"4","author":"Thompson","year":"2007","journal-title":"Proc Am Thorac Soc"},{"key":"2026012203473706400_bib38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pec.2014.01.003","article-title":"Patient preferences and performance bias in a weight loss trial with a usual care arm","volume":"95","author":"McCambridge","year":"2014","journal-title":"Patient Educ Couns"},{"key":"2026012203473706400_bib39","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1513\/pats.200706-073JK","article-title":"Placebo versus best-available-therapy control group in clinical trials for pharmacologic therapies: which is better?","volume":"4","author":"Castro","year":"2007","journal-title":"Proc Am Thorac Soc"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/18\/4\/590\/66338913\/annalsats_18_4_590.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/18\/4\/590\/66338913\/annalsats_18_4_590.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:53:19Z","timestamp":1769071999000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/18\/4\/590\/8419563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,1]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202008-940oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4]]},"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"2020-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}